Log In Sign up
The largest database of trusted experimental protocols

Anti pd 1 or hamster igg isotype control

Manufactured by BioXCell
Visit Supplier

Anti–PD-1 or hamster IgG isotype control is a laboratory reagent used in research applications. It functions as a control for experiments involving the programmed cell death-1 (PD-1) receptor.

Automatically generated - may contain errors

Lab products found in correlation

Tamoxifen, by Merck Group (2 mentions) Metformin, by Cayman Chemical (1 mentions)

Spelling variants of this product

Anti-PD-1 (65 citations) Control IgG (30 citations) Isotype control (29 citations) IgG isotype control (25 citations) Hamster IgG (18 citations) Control Hamster IgG (7 citations) Isotype IgG (5 citations) Hamster IgG isotype control (3 citations)

4 protocols using anti pd 1 or hamster igg isotype control

1

Metformin and Anti-PD-1 Combination Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
On day 5, when there were 1–10 mm2 palpable tumors, mice were started on either 0.2mg anti–PD-1 or hamster IgG isotype control (Bio X Cell), injected every 4 days intraperitoneally, and metformin (50 mg/kg, Cayman Chemical) or PBS, injected every 2 days intraperitoneally. Cohorts were sacrificed when control mouse tumors reached 15 mm in any direction measured. For metformin drinking water cohorts, mice with 1–10mm2 palpable tumors started on 1g/L metformin drinking water, and were injected with anti–PD-1 every 4 days intraperitoneally. Cohorts were sacrificed when control mouse tumors reached 15 mm in any direction measured.
Scharping N.E., Menk A.V., Whetstone R.D., Zeng X, & Delgoffe G.M. (2016). Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer immunology research, 5(1), 9-16.
+ Open protocol
+ Expand
2

Tumor Growth and MCT1 Deletion in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Slc16a1f/fFoxp3Cre or Foxp3Cre mice were inoculated with 1.5 x 105 B16-F10 cells in complete RPMI media. To monitor tumor growth, tumors area was determined 3x weekly using digital calipers and stopped once tumors reached 15mm in any direction. For 3MP treated mice, Foxp3Cre or Foxp3Cre.ERT2 mice were inoculated with 1.5 x 105 B16-F10 cells. Starting on day 10 or 12 post tumor inoculation mice were treated daily either with water or 25 mg/kg 3MP (Caymen Chemical) via intraperitoneal (I.P.) injection. On day 14 one hour prior to sacrifice, mice were given a final dose of 25 mg/kg 3MP or water. For 3MP tumor growth, treatment started day 7 post tumor injection and continued daily with 25 mg/kg 3MP or H2O I.P. until tumors reached 15mm in any direction.
For the inducible deletion of MCT1 (Slc16a1) Slc16a1f/fFoxp3GFP.Cre.ERT2 or Foxp3GFP.Cre.ERT2 mice were treated I.P. or P.O. with 1 mg of tamoxifen (T5648, Sigma) in corn oil (C8267, Sigma) from day −4 to 0. On day 0, mice were inoculated intradermally with 2.5x105 B16-F10, MC38, or MEER cells in complete RPMI media and given a dose of 1mg tamoxifen. tamoxifen treatment continued 3x weekly until the conclusion of the experiment. On day 7, when tumors reached 1-10 mm2 mice were treated with 0.2mg anti–PD-1 or hamster IgG isotype control (Bio X Cell) 3x weekly until the conclusion of the experiment.
Watson M.J., Vignali P.D., Mullett S.J., Overacre-Delgoffe A.E., Peralta R.M., Grebinoski S., Menk A.V., Rittenhouse N.L., DePeaux K., Whetstone R.D., Vignali D.A., Hand T.W., Poholek A.C., Morrison B.M., Rothstein J.D., Wendell S.G, & Delgoffe G.M. (2021). Metabolic support of tumor-infiltrating regulatory T cells by lactic acid. Nature, 591(7851), 645-651.
+ Open protocol
+ Expand
3

Tumor Growth and MCT1 Deletion in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Slc16a1f/fFoxp3Cre or Foxp3Cre mice were inoculated with 1.5 x 105 B16-F10 cells in complete RPMI media. To monitor tumor growth, tumors area was determined 3x weekly using digital calipers and stopped once tumors reached 15mm in any direction. For 3MP treated mice, Foxp3Cre or Foxp3Cre.ERT2 mice were inoculated with 1.5 x 105 B16-F10 cells. Starting on day 10 or 12 post tumor inoculation mice were treated daily either with water or 25 mg/kg 3MP (Caymen Chemical) via intraperitoneal (I.P.) injection. On day 14 one hour prior to sacrifice, mice were given a final dose of 25 mg/kg 3MP or water. For 3MP tumor growth, treatment started day 7 post tumor injection and continued daily with 25 mg/kg 3MP or H2O I.P. until tumors reached 15mm in any direction.
For the inducible deletion of MCT1 (Slc16a1) Slc16a1f/fFoxp3GFP.Cre.ERT2 or Foxp3GFP.Cre.ERT2 mice were treated I.P. or P.O. with 1 mg of tamoxifen (T5648, Sigma) in corn oil (C8267, Sigma) from day −4 to 0. On day 0, mice were inoculated intradermally with 2.5x105 B16-F10, MC38, or MEER cells in complete RPMI media and given a dose of 1mg tamoxifen. tamoxifen treatment continued 3x weekly until the conclusion of the experiment. On day 7, when tumors reached 1-10 mm2 mice were treated with 0.2mg anti–PD-1 or hamster IgG isotype control (Bio X Cell) 3x weekly until the conclusion of the experiment.
Watson M.J., Vignali P.D., Mullett S.J., Overacre-Delgoffe A.E., Peralta R.M., Grebinoski S., Menk A.V., Rittenhouse N.L., DePeaux K., Whetstone R.D., Vignali D.A., Hand T.W., Poholek A.C., Morrison B.M., Rothstein J.D., Wendell S.G, & Delgoffe G.M. (2021). Metabolic support of tumor-infiltrating regulatory T cells by lactic acid. Nature, 591(7851), 645-651.
+ Open protocol
+ Expand
4

Melanoma Tumor Growth and Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
C57BL/6J mice were injected with CL24hygro or CL24leptin melanoma cell line (250,000 cells intradermally) on day 0 and followed until tumors reach 15 mm in any direction. Tumors were measured every other day with digital calipers and tumor size was calculated by LxW.
Tumors (CL24, MC38 and PanCO2) were treated with PBS, VVctrl or VVleptin (2.5x106 PFU) intratumorally when tumors reached approximately a 20mm2 and tumor growth was monitored until tumors treated with PBS reached 15mm in any direction. For CD8 depletion experiments mice were injected every other day starting at day 0 with anti-CD8 (YTS) at 200ug per mouse. On day 7 mice were injected with CL24hygro or CL24leptin melanoma cell line (250,000 cells intradermally) and followed until tumor reach 15mm in any direction.
On day 7 when tumors reached 5mm diameter, mice were treated with Vaccinia virus as previously described and were started on either 0.2mg anti– PD1 or hamster IgG isotype control (Bio X Cell), injected every other day days intraperitoneally. Cohorts were sacrificed when control mouse tumors reached 15 mm in any direction measured.
Rivadeneira D.B., DePeaux K., Wang Y., Kulkarni A., Tabib T., Menk A.V., Sampath P., Lafyatis R., Ferris R.L., Sarkar S.N., Thorne S.H, & Delgoffe G.M. (2019). Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity, 51(3), 548-560.e4.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!